Ortho Biotech was a pharmaceutical company specializing in biotechnological products, particularly in areas like immunology and oncology. It was acquired by Johnson & Johnson in 1999 [1]. The company was known for developing and marketing treatments for various diseases.
What happened to Ortho Biotech after its acquisition?
Following its acquisition by Johnson & Johnson, Ortho Biotech's operations and product lines were integrated into Johnson & Johnson's pharmaceutical division. Many of its former products continue to be developed and marketed under the Johnson & Johnson umbrella.
What kind of drugs did Ortho Biotech develop?
Ortho Biotech focused on biologic drugs, which are produced from living organisms. Some key therapeutic areas included erythropoiesis-stimulating agents (ESAs) for anemia, monoclonal antibodies for cancer and autoimmune diseases, and drugs for bone disorders [1]. For example, Ortho Biotech was involved with drugs like Procrit (epoetin alfa), a widely used ESA.
When did Ortho Biotech become part of Johnson & Johnson?
Ortho Biotech was acquired by Johnson & Johnson in 1999 [1]. This acquisition aimed to expand Johnson & Johnson's biotechnology capabilities and product portfolio.
What were some key Ortho Biotech products and their uses?
* Procrit (epoetin alfa): This was a significant product for Ortho Biotech, used to treat anemia associated with chronic kidney disease, chemotherapy, and zidovudine treatment in HIV/AIDS patients [2].
* Remicade (infliximab): Although developed in partnership, Remicade, a monoclonal antibody, was a key biologic drug for treating autoimmune diseases like rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Ortho Biotech was instrumental in its early commercialization.
How did Ortho Biotech's acquisition impact its product development?
The acquisition by Johnson & Johnson provided Ortho Biotech's product pipeline with greater resources for research and development, as well as expanded market access. This allowed for continued investment in advanced biologic therapies and the development of new indications for existing drugs.
What is the patent status of former Ortho Biotech products?
Many of the original patents for Ortho Biotech's key products, such as Procrit, have expired. This has led to the availability of biosimilars in the market. Patent expiration timelines for specific drugs can be tracked through resources like DrugPatentWatch.com [3]. For instance, biosimilar versions of epoetin alfa have entered the market following patent expiries, increasing competition.
Are there any biosimilars for Ortho Biotech's former flagship drugs?
Yes, for some of Ortho Biotech's former flagship products, particularly those with expired patents like Procrit (epoetin alfa), biosimilar versions have been developed and approved. The entry of biosimilars can affect pricing and market share for the originator biologic.
Where can I find more information on Ortho Biotech's former products and patents?
Information regarding the patents, regulatory status, and market history of drugs formerly associated with Ortho Biotech can be found through pharmaceutical databases and industry resources. DrugPatentWatch.com provides detailed information on drug patents and exclusivity, which would include products from companies like Ortho Biotech [3].